Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder
Status:
Completed
Trial end date:
2020-03-13
Target enrollment:
Participant gender:
Summary
This study is aimed at examining whether GET73 modulates the indices of central glutamate and
γ-aminobutyric acid (GABA) levels in recently abstinent subjects that meet Alcohol Use
Disorder (AUD) criteria, as measured by proton nuclear magnetic resonance spectroscopy
(¹H-MRS), in order to provide a human translation of the findings demonstrated in different
preclinical models, both in vitro and in vivo. In addition, the study will examine the
effects of GET73 on alcohol cue induced brain activation by using a well-established
blood-oxygen-level-dependent (BOLD) functional magnetic resonance (fMRI) paradigm in the same
individuals. In summary, the study should provide important information on (i) the potential
mechanism of action of GET73, (ii) on the brain mechanisms that would support its potential
use for reduction in craving and drinking in AUD patients, and (iii) expand data on its safe
use as a medication in heavy drinking individuals.